PT828500E - Utilizacao de flavanolignanos para a preparacao de medicamentos com actividade antiproliferativa no utero ovarios e mama - Google Patents

Utilizacao de flavanolignanos para a preparacao de medicamentos com actividade antiproliferativa no utero ovarios e mama

Info

Publication number
PT828500E
PT828500E PT95935927T PT95935927T PT828500E PT 828500 E PT828500 E PT 828500E PT 95935927 T PT95935927 T PT 95935927T PT 95935927 T PT95935927 T PT 95935927T PT 828500 E PT828500 E PT 828500E
Authority
PT
Portugal
Prior art keywords
silicristin
silidianin
mixtures
effective amount
therapeutically effective
Prior art date
Application number
PT95935927T
Other languages
English (en)
Inventor
Ezio Bombardelli
Paolo Morazzoni
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Publication of PT828500E publication Critical patent/PT828500E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT95935927T 1995-05-23 1995-10-10 Utilizacao de flavanolignanos para a preparacao de medicamentos com actividade antiproliferativa no utero ovarios e mama PT828500E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI951047A IT1274549B (it) 1995-05-23 1995-05-23 Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno

Publications (1)

Publication Number Publication Date
PT828500E true PT828500E (pt) 2004-08-31

Family

ID=11371650

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95935927T PT828500E (pt) 1995-05-23 1995-10-10 Utilizacao de flavanolignanos para a preparacao de medicamentos com actividade antiproliferativa no utero ovarios e mama

Country Status (21)

Country Link
US (2) US5912265A (pt)
EP (1) EP0828500B1 (pt)
JP (1) JP3178844B2 (pt)
KR (1) KR100290030B1 (pt)
CN (1) CN1148181C (pt)
AT (1) ATE268183T1 (pt)
AU (1) AU709802B2 (pt)
CA (1) CA2221753C (pt)
DE (1) DE69533112T2 (pt)
DK (1) DK0828500T3 (pt)
ES (1) ES2222466T3 (pt)
FI (1) FI119100B (pt)
HK (1) HK1006222A1 (pt)
HU (1) HU220627B1 (pt)
IT (1) IT1274549B (pt)
NO (1) NO317153B1 (pt)
PL (1) PL182064B1 (pt)
PT (1) PT828500E (pt)
RU (1) RU2161488C2 (pt)
SI (1) SI0828500T1 (pt)
WO (1) WO1996037209A1 (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2432560A1 (fr) 1978-08-02 1980-02-29 Texas Instruments Inc Procede de decapage de metaux, en particulier d'aluminium, au plasma de tetrachlorure de silicium
US6379714B1 (en) 1995-04-14 2002-04-30 Pharmaprint, Inc. Pharmaceutical grade botanical drugs
DK0918746T3 (da) * 1996-08-12 2003-08-04 Celgene Corp Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauer
US6239114B1 (en) * 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
FR2792846B1 (fr) 1999-04-30 2001-07-27 Salomon Sa Patin a roues en ligne du type a platine superieure articulee
WO2000066232A2 (fr) 1999-04-30 2000-11-09 Salomon S.A. Chassis articule
KR100342942B1 (ko) * 1999-07-05 2002-07-02 민경윤 카르두스 마리아누스 추출물 또는 이로부터 정제된 실리빈을함유하는 경구용 마이크로에멀젼 조성물
US20010025027A1 (en) * 2000-03-07 2001-09-27 Sonis Stephen T. Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
WO2002067853A2 (en) * 2000-10-06 2002-09-06 Probiochem, Llc A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine
WO2002083124A1 (en) * 2000-10-06 2002-10-24 Probiochem, Llc A composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
DE60130799T2 (de) * 2000-11-30 2008-07-17 Children's Medical Center Corp., Boston Synthese von 4-aminothalidomid enantiomeren
US20040092565A1 (en) * 2001-07-25 2004-05-13 George Kindness Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
EP1314438A1 (en) * 2001-11-23 2003-05-28 Nutricia N.V. Anti-proliferative composition
JP2006510606A (ja) * 2002-10-15 2006-03-30 セルジーン・コーポレーション 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物
EP1562597A4 (en) * 2002-10-31 2008-05-14 Celgene Corp COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MACULAR DEGENERATION AND METHODS OF USE THEREOF
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
JP2006507324A (ja) * 2002-11-06 2006-03-02 セルジーン・コーポレーション 骨髄増殖性疾患を治療および管理するための選択的サイトカイン阻害薬を含む組成物およびその使用法
CA2506442A1 (en) * 2002-11-18 2004-07-01 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
WO2004045597A1 (en) * 2002-11-18 2004-06-03 Celgene Corporation Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CN100402023C (zh) * 2003-06-21 2008-07-16 山东绿叶天然药物研究开发有限公司 一种水飞蓟素软胶囊及其制备方法
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
KR100577514B1 (ko) * 2003-10-21 2006-05-10 한미약품 주식회사 비페닐디메틸디카복실레이트, 및 카르두스 마리아누스추출물 또는 이로부터 정제된 실리빈을 함유하는 경구용마이크로에멀젼 조성물
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
CN1980668A (zh) * 2004-01-28 2007-06-13 安德鲁科技有限公司 通过作用于类固醇依赖性基因激活路径不同步骤中抑制剂的组合而增强抗雄激素活性及用途
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
AU2004319759A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
ZA200609228B (en) * 2004-04-23 2008-05-28 Celgene Corp Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
JP5578785B2 (ja) 2005-08-31 2014-08-27 セルジーン コーポレイション イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
UA94964C2 (ru) 2006-09-26 2011-06-25 Селджин Корпорэйшн Производные 5-замещенного хиназолинона, композиция, которая их содержит, и их применение
CN105693730A (zh) 2006-10-19 2016-06-22 西格诺药品有限公司 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途
MX2009007345A (es) 2007-01-08 2010-02-22 Androscience Corp Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo.
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US7907654B2 (en) * 2007-04-27 2011-03-15 Hewlett-Packard Development Company, L.P. Laser diode with a grating layer
EP2175726A4 (en) 2007-07-31 2011-01-05 Androscience Corp COMPOSITIONS WITH ANDROGEN RECEPTOR DERIVATIVES AND METHOD FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF SKIN DISEASES OR HAIR LOSS
NZ584425A (en) 2007-09-26 2012-03-30 Celgene Corp 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
CZ2008407A3 (cs) * 2008-06-26 2009-08-26 Agra Group, A. S. Vodorozpustný prípravek na bázi flavanonol lignanu a zpusob jeho prípravy
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
SI2358697T1 (sl) 2008-10-29 2016-02-29 Celgene Corporation Spojine izoindolina za uporabo pri zdravljenju raka
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
TR201905423T4 (tr) 2009-05-19 2019-05-21 Celgene Corp 4-amino-2-(2,6-dioksopiperidin-3-il)izindolin-1,3-dion'un formülasyonları
KR20120113219A (ko) 2009-12-22 2012-10-12 셀진 코포레이션 (메틸술포닐)에틸 벤젠 이소인돌린 유도체 및 그의 치료 용도
WO2011100380A1 (en) 2010-02-11 2011-08-18 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
WO2012096884A1 (en) 2011-01-10 2012-07-19 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
SI2683708T1 (en) 2011-03-11 2018-05-31 Celgene Corporation 3- (5-AMINO-2-METHYL-4-OXO-4H-QUINASOLIN-3-YL) -PYPERIDIN-2,6-DION, AND THEIR PHARMACEUTICAL COMPOSITION AND TYPES OF USE
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
KR20140063808A (ko) 2011-09-14 2014-05-27 셀진 코포레이션 시클로프로판카르복실 산｛２-[(１s)-１-(３-에톡시-４-메톡시-페닐)-２-메탄술포닐-에틸]-３-옥소-２,３-디하이드로-１h-이소인돌-４-일｝-아마이드의 제제
KR20210033073A (ko) 2011-12-27 2021-03-25 암젠 (유럽) 게엠베하 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
NZ628030A (en) 2012-08-09 2016-12-23 Celgene Corp Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
EP2752201A1 (en) 2013-01-04 2014-07-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. C-terminal HSP90 inhibitors to treat pituitary adenomas
WO2014110558A1 (en) 2013-01-14 2014-07-17 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
TWI546722B (zh) * 2013-12-11 2016-08-21 新益先創科技股份有限公司 控制點感測面板及控制點感測面板設計方法
WO2015108889A1 (en) 2014-01-15 2015-07-23 Celgene Corporation Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
US20170172921A1 (en) * 2016-12-14 2017-06-22 Mahmoud Reza Jaafari Polyphenolic compounds encapsualated in long circulating liposomes and use thereof
AU2019281613B2 (en) * 2018-06-09 2022-09-08 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Compound for treatment or prevention of liver diseases
CN109432084A (zh) * 2018-12-26 2019-03-08 温州医科大学 一种抗癌组合物及其在药物制备中的应用
CN112494479B (zh) * 2020-12-28 2022-06-21 华中科技大学同济医学院附属同济医院 茶黄素在制备卵巢功能保护药物方面的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2261434A (en) * 1991-11-15 1993-05-19 Inverni Della Beffa Spa New radical scavenging and antipoperoxidant flavanolignans their preparation and formulations for therapeutic use
CN1047944C (zh) * 1993-06-26 2000-01-05 曾庆通 一种治疗慢性肝炎的中药胶囊

Also Published As

Publication number Publication date
DE69533112D1 (de) 2004-07-08
NO317153B1 (no) 2004-08-30
JP3178844B2 (ja) 2001-06-25
ATE268183T1 (de) 2004-06-15
AU709802B2 (en) 1999-09-09
ITMI951047A0 (it) 1995-05-23
RU2161488C2 (ru) 2001-01-10
EP0828500B1 (en) 2004-06-02
NO975334D0 (no) 1997-11-20
NO975334L (no) 1997-11-20
DE69533112T2 (de) 2004-10-21
PL323450A1 (en) 1998-03-30
CN1148181C (zh) 2004-05-05
IT1274549B (it) 1997-07-17
PL182064B1 (pl) 2001-10-31
HU220627B1 (hu) 2002-03-28
HK1006222A1 (en) 1999-02-19
KR19990014941A (ko) 1999-02-25
CA2221753A1 (en) 1996-11-28
FI974268A (fi) 1997-12-02
US6218369B1 (en) 2001-04-17
ES2222466T3 (es) 2005-02-01
CA2221753C (en) 2001-07-24
HUT77966A (hu) 1998-12-28
WO1996037209A1 (en) 1996-11-28
FI974268A0 (fi) 1997-11-18
AU3805195A (en) 1996-12-11
CN1185112A (zh) 1998-06-17
JPH10511685A (ja) 1998-11-10
ITMI951047A1 (it) 1996-11-23
EP0828500A1 (en) 1998-03-18
SI0828500T1 (en) 2004-10-31
DK0828500T3 (da) 2004-08-16
KR100290030B1 (ko) 2001-05-15
FI119100B (fi) 2008-07-31
US5912265A (en) 1999-06-15

Similar Documents

Publication Publication Date Title
PT828500E (pt) Utilizacao de flavanolignanos para a preparacao de medicamentos com actividade antiproliferativa no utero ovarios e mama
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
GR3034535T3 (en) Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer
BR0012488A (pt) Composição farmacêutica, métodos para melhorar a taxa de absorção de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para melhorar o inìcio do benefìcio terapêutico de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para inibição de gastroirritação em um mamìfero, e para tratamento de mamìferos necessitando do tratamento proporcionado por um ou mais do que um agente farmaceuticamente ativo, e, processo para preparar uma composição farmacêutica
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
HU9401106D0 (en) Enhanced skin penetration system for imporoved topical delivery of drugs
YU13603A (sh) Postupci tretiranja poremećaja povenzanih sa bcl-2 primenom bcl-2 antisens oligomera
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
MX9100042A (es) Reduccion o prevencion de irritacion de la piel por drogas
AU4258101A (en) Combination therapies with vascular damaging activity
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
MY124465A (en) Reduction of infarct volume using citicoline
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
TR200401810T4 (tr) Kısırlık tedavisinde fsh'ın kullanılması
EP1073436A4 (en) IMPROVED METHOD FOR ERADICATION OF HELICOBACTER PYLORI
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
GB9930077D0 (en) Medicaments
BR0008677A (pt) Composto de tiazolindolinona, composição farmacêutica, e, métodos papa preparar um composto de tiazolindolinona, e de prevenção/reduçao da severidade dos efeitos colaterais de citotoxicidade epitelial da quimioterapia e/ou terapia de radiação
PL335419A1 (en) Anti-infertility and fertility enhancing drug
IL129267A (en) Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence